Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Mohamed El Kassas, Mohamed Eltabbakh, Mohamed Elbadry, Ahmed Tawheed & Tamer Elbaz. (2022) Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Current Medical Research and Opinion 38:4, pages 553-563.
Read now
Read now
Samar E. Ghanem, Maha Elsabaawy, Nashwa shebl, Eman Abdelsameea, Warda Othman, Fathia I. EL‑Bassal, Gamalat A. Elgedawy, Dalia M. Elsabaawy & Marwa L. Helal. (2020) Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Review of Anti-infective Therapy 18:9, pages 947-954.
Read now
Read now
Stefania Paolucci, Federica Novazzi, Antonio Piralla, Renato Maserati, Roberto Gulminetti, Stefano Novati, Giorgio Barbarini, Paolo Sacchi, Alice Fratini, Laura Bellotti & Fausto Baldanti. (2019) Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. Infection and Drug Resistance 12, pages 1975-1984.
Read now
Read now
Carol Stanciu, Anca Trifan, Cristina Muzica & Catalin Sfarti. (2019) Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opinion on Pharmacotherapy 20:4, pages 379-384.
Read now
Read now
Isabella Esposito, Sebastián Marciano & Julieta Trinks. (2018) Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 649-657.
Read now
Read now
Rebecca Voaklander & Ira M Jacobson. (2017) Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Review of Gastroenterology & Hepatology 11:9, pages 789-795.
Read now
Read now
Vicente Soriano, Laura Benítez-Gutiérrez, Ana Arias, Itziar Carrasco, Pablo Barreiro, Jose M. Peña & Carmen de Mendoza. (2017) Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 13:9, pages 1015-1022.
Read now
Read now
Vincent Soriano, José V. Fernandez-Montero, Carmen de Mendoza, Laura Benitez-Gutierrez, José M. Peña, Ana Arias & Pablo Barreiro. (2017) Treatment of hepatitis C with new fixed dose combinations. Expert Opinion on Pharmacotherapy 18:12, pages 1235-1242.
Read now
Read now
Isabella Esposito, Julieta Trinks & Vicente Soriano. (2016) Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opinion on Drug Metabolism & Toxicology 12:10, pages 1197-1209.
Read now
Read now
Articles from other publishers (38)
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, Chi-Yi Chen, Ching-Chu Lo, Kuo-Chih Tseng, Pei-Yuan Su, Wei-Yu Kao, Ming-Chang Tsai, Hung-Da Tung, Hao-Tsai Cheng, Fu-Jen Lee, Chia-Sheng Huang, Ke-Jhang Huang, Yu-Lueng Shih, Sheng-Shun Yang, Jo-Hsuan Wu, Hsueh-Chou Lai, Yu-Jen Fang, Po-Yueh Chen, Jow-Jyh Hwang, Chi-Wei Tseng, Wei-Wen Su, Chun-Chao Chang, Pei-Lun Lee, Jyh-Jou Chen, Chi-Yang Chang, Tsai‐Yuan Hsieh, Chung-Hsin Chang, Yi-Jie Huang & Jia-Horng Kao. (2023) Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatology International 17:2, pages 291-302.
Crossref
Crossref
Haesuk Park, Wei-Hsuan Lo-Ciganic, James Huang, Yonghui Wu, Linda Henry, Joy Peter, Mark Sulkowski & David R. Nelson. (2022) Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Scientific Reports 12:1.
Crossref
Crossref
Maria Antonia De Francesco, Franco Gargiulo, Serena Zaltron, Angiola Spinetti, Francesco Castelli & Arnaldo Caruso. (2022) DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b. International Journal of Environmental Research and Public Health 19:18, pages 11655.
Crossref
Crossref
Ottavia Giampaoli, Fabio Sciubba, Elisa Biliotti, Mariangela Spagnoli, Riccardo Calvani, Alberta Tomassini, Giorgio Capuani, Alfredo Miccheli & Gloria Taliani. (2022) Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients. International Journal of Molecular Sciences 23:17, pages 10043.
Crossref
Crossref
Jing Xie, Bin Xu, Linlin Wei, Chunyang Huang & Wei Liu. (2022) Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis. Infectious Diseases and Therapy 11:4, pages 1661-1682.
Crossref
Crossref
Haesuk Park, Wei‐Hsuan Lo‐Ciganic, James Huang, Yonghui Wu, Linda Henry, Joy Peter, Mark Sulkowski & David R. Nelson. (2022) Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis. Hepatology 76:2, pages 483-491.
Crossref
Crossref
Eriko Ohsaki, Yadarat Suwanmanee & Keiji Ueda. (2021) Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 13:9, pages 1691.
Crossref
Crossref
Anshuman Elhence, Achintya Singh, Abhinav Anand, Ramesh Kumar, Anzar Ashraf, Sonu Kumar, Dibyabhaba Pradhan, Piyush Pathak, Manas Vaishnav, Mahendra Singh Rajput, Vikas Banyal, Baibaswata Nayak & Shalimar. (2021) Real‐world re‐treatment outcomes of direct‐acting antiviral therapy failure in patients with chronic hepatitis C. Journal of Medical Virology 93:8, pages 4982-4991.
Crossref
Crossref
Omar A. Saldarriaga, Bradley Dye, Judy Pham, Timothy G. Wanninger, Daniel Millian, Michael Kueht, Benjamin Freiberg, Netanya Utay & Heather L. Stevenson. (2021) Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome. Scientific Reports 11:1.
Crossref
Crossref
Irene Pericot‐Valverde, Lior Rennert, Moonseong Heo, Matthew J. Akiyama, Briana L. Norton, Linda Agyemang, Brandon Lumsden & Alain H. Litwin. (2020) Rates of perfect self‐reported adherence to direct‐acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study. Journal of Viral Hepatitis 28:3, pages 548-557.
Crossref
Crossref
Saima Mushtaq, Atika Mansoor, Muhammad Umar, Amjad Khan, Saima Siddiqi & Sobia Manzoor. (2020) Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan. Journal of Medical Virology 92:12, pages 3475-3487.
Crossref
Crossref
Fahimeh Safarnezhad Tameshkel, Mohammad Hadi Karbalaie Niya, Farhad Zamani, Nima Motamed, Hossein Ajdarkosh, Jamshid Vafaeimanesh, Mahmoodreza Khoonsari, Masood Reza Sohrabi, Sima Aten, Azita Azarkeivan, Masoumeh Sadat Eslami, Dhayaneethie Perumal, Mansooreh Maadi, Behrooz Ghanbari & Hossein Keyvani. (2020) Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study. Archives of Virology 165:10, pages 2193-2203.
Crossref
Crossref
Mohamed El Kassas, Mohamed Alboraie, Mohamed El Badry, Naglaa Youssef, Heba Omar, Reem Y. El Sheemy, Amira Al Balakosy, Ossama Ashraf Ahmed Mohamed, Gina Gamal Naguib Meleak, Hany Dabbous, Mohamed Hassan Ahmed Fouad, Mohamed-Naguib Wifi, Samy Zaky, Marwa Tahoon, Adel El Tahan, Fathiya El-Raey, Sameera Ezzat & Wahid Doss. (2020) Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study. International Journal of Infectious Diseases 96, pages 367-370.
Crossref
Crossref
Grace Zhang, Krupa Patel, Akshata Moghe, Andrea Reid, Marina Serper, Linda Calgaro, Sandra Gibson, Susan Zickmund, Obaid Shaikh & Shari Rogal. (2019) Provider Perceptions of Hepatitis C Treatment Adherence and Initiation. Digestive Diseases and Sciences 65:5, pages 1324-1333.
Crossref
Crossref
Yuhei Saito, Michio Imamura, Takuro Uchida, Mitsutaka Osawa, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Masahiro Serikawa, Hiroshi Aikata, Hiromi Abe‐Chayama, C. Nelson Hayes & Kazuaki Chayama. (2019) Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. Journal of Medical Virology 92:2, pages 210-218.
Crossref
Crossref
I. W. FongI. W. Fong. 2020. Current Trends and Concerns in Infectious Diseases. Current Trends and Concerns in Infectious Diseases
103
129
.
Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele'Tommaso Trenti. (2019) New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. Journal of Clinical and Experimental Hepatology 9:4, pages 522-538.
Crossref
Crossref
Abdel-Fattah Attia, Nadia Madany, Lamiaa Madkour, Sahar Maklad & Ashgan Zayed. (2019) The Negative Effect of Epstein-Barr Virus on the Response of Hepatitis C Virus Patients to Interferon-ribavirin Therapy. Journal of Pure and Applied Microbiology 13:2, pages 1191-1198.
Crossref
Crossref
Panita Mettikanont, Chalermrat Bunchorntavakul & K. Rajender Reddy. (2019) Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Alimentary Pharmacology & Therapeutics 49:5, pages 492-505.
Crossref
Crossref
Clara Y. Tow & John F. Reinus. (2019) Ineffective Absorption? Failure of Direct-Acting Therapy for Chronic Hepatitis C in Cirrhotic Patients With Roux-en-Y Gastric Bypass. Journal of Investigative Medicine High Impact Case Reports 7, pages 232470961985812.
Crossref
Crossref
Matthew J. Akiyama, Linda Agyemang, Julia H. Arnsten, Moonseong Heo, Brianna L. Norton, Bruce R. Schackman, Benjamin P. Linas & Alain H. Litwin. (2018) Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infectious Diseases 18:1.
Crossref
Crossref
Snezana Jovanovic-Cupic, Ana Bozovic, Milena Krajnovic & Nina Petrovic. 2018. Hepatitis C - From Infection to Cure. Hepatitis C - From Infection to Cure.
Jean-Baptiste Trabut, Camille Barrault, Hélène Charlot, Damien Carmona, Anne Bourdel, Mustapha Benslimane, Murielle François, Willy Kini-Matondo, Richard Causse, Françoise Roudot-Thoraval & Christophe Hézode. (2018) Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder. Journal of Addiction Medicine 12:5, pages 346-352.
Crossref
Crossref
Victor Virlogeux, Pascale Berthillon, Isabelle Bordes, Sylvie Larrat, Stéphanie Crouy, Caroline Scholtès, Pierre Pradat, Marianne Maynard, Fabien Zoulim, Vincent Leroy, Isabelle Chemin, Christian Trépo & Marie-Anne Petit. (2018) Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy. Clinics and Research in Hepatology and Gastroenterology 42:4, pages 313-318.
Crossref
Crossref
Navaneethan Palanisamy, Prabhav Kalaghatgi, Dario Akaberi, Åke Lundkvist, Zhi-wei Chen, Peng Hu & Johan Lennerstrand. (2017) Worldwide Prevalence of Baseline Resistance-Associated Polymorphisms and Resistance Mutations in HCV against Current Direct-Acting Antivirals. Antiviral Therapy 23:6, pages 485-493.
Crossref
Crossref
Issifou Yaya, Perrine Roux, Fabienne Marcellin, Linda Wittkop, Laure Esterle, Bruno Spire, Stéphanie Dominguez, Boni Armand Elegbe, Lionel Piroth, Philippe Sogni, Dominique Salmon-Ceron & Maria Patrizia Carrieri. (2018) Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLOS ONE 13:7, pages e0199874.
Crossref
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda & Marc Sáez-Zafra. (2018) Comorbilidad, medicación concomitante, uso de recursos y costes sanitarios asociados a los pacientes portadores del virus de la hepatitis C crónica en España. Gastroenterología y Hepatología 41:4, pages 234-244.
Crossref
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda & Marc Sáez-Zafra. (2018) Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterología y Hepatología (English Edition) 41:4, pages 234-244.
Crossref
Crossref
Itzíar Carrasco, Ana Arias, Laura Benítez-Gutiérrez, Gemma Lledó, Silvia Requena, Miriam Cuesta, Valentín Cuervas-Mons & Carmen de Mendoza. (2018) Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. Journal of Medical Virology 90:3, pages 532-536.
Crossref
Crossref
John T. Randolph, A. Chris Krueger, Pamela L. Donner, John K. Pratt, Dachun Liu, Christopher E. Motter, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Hock B. Lim, Jill M. Beyer, Rubina Mondal, Neeta S. Panchal, Lynn Colletti, Yaya Liu, Gennadiy Koev, Warren M. Kati, Lisa E. Hernandez, David W. A. Beno, Kenton L. Longenecker, Kent D. Stewart, Emily O. Dumas, Akhteruzzaman Molla & Clarence J. Maring. (2018)
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a
trans
-Stilbene Analog with Good Oral Bioavailability
. Journal of Medicinal Chemistry 61:3, pages 1153-1163.
Crossref
Crossref
Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel & Thomas F. Baumert. (2018) Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therapeutic Advances in Gastroenterology 11, pages 175628481875948.
Crossref
Crossref
Edward R. Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks & Wm. Christopher Mathews. (2017) Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment. AIDS Research and Therapy 14:1.
Crossref
Crossref
Stefania Paolucci, Marta Premoli, Stefano Novati, Roberto Gulminetti, Renato Maserati, Giorgio Barbarini, Paolo Sacchi, Antonio Piralla, Davide Sassera, Leone De Marco, Alessia Girello, Mario U. Mondelli & Fausto Baldanti. (2017) Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Scientific Reports 7:1.
Crossref
Crossref
Isabella Esposito, Laura Benítez-Gutiérrez, Ana Treviño, Ana Arias, Maria Jesus Citores, Silvia Requena, Vicente Soriano, Valentín Cuervas-Mons & Carmen De Mendoza. (2016)
Impact of
ITPA
Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C
. Antiviral Therapy 22:7, pages 571-575.
Crossref
Crossref
Stefania Paolucci, Marta Premoli, Serena Ludovisi, Mario U Mondelli & Fausto Baldanti. (2016) HCV Intergenotype 2k/1b Recombinant Detected in a DAA-Treated Patient in Italy. Antiviral Therapy 22:4, pages 365-368.
Crossref
Crossref
Ana Arias, Antonio Aguilera, Vicente Soriano, Laura Benítez-Gutiérrez, Gemma Lledó, Daniel Navarro, Ana Treviño, Esteban Otero, José M Peña, Valentín Cuervas-Mons & Carmen de Mendoza. (2016) Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. Antiviral Therapy 22:4, pages 307-312.
Crossref
Crossref
K. Yu. Kokina, A. O. Bueverov, P. O. Bogomolov & M. V. Matsievich. (2017) Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1. Terapevticheskii arkhiv 89:12, pages 197.
Crossref
Crossref
Jean-Pierre Routy, Christina Psomas, Vicente Soriano, Patrick Philibert, Hervé Tissot-Dupont & Alain Lafeuillade. (2016) Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID). Journal of Virus Eradication 2:3, pages 187-192.
Crossref
Crossref